News

January 22, 2020

First Patient Dosed in Phase 1/2 Trial Testing HB-201 Vaccine for HPV16+ Cancers, Hookipa Pharma Announces

News

The first patient has been dosed in a Phase 1/2 trial testing Hookipa Pharma‘s experimental cancer vaccine HB-201, alone or in combination with an immune checkpoint inhibitor, in people ... Read more

January 20, 2020

FDA Grants Priority Review to Opdivo-Yervoy Combo as First-Line Treatment for Advanced NSCLC

News

The U.S. Food and Drug Administration (FDA) has agreed to a priority review of Bristol-Myers Squibb’s application for expanding the label of Opdivo (nivolumab), combined with Yervoy (ipilimumab), as ... Read more

January 17, 2020January 17, 2020

Phase 2 Trial in Belarus Examines DNA Vaccine, Elenagen, for Advanced Solid Cancers

News

The Alexandrov National Cancer Centre in Belarus has initiated a Phase 2 clinical trial to test a new DNA vaccine, Elenagen, in patients with inoperable, late-stage cancers affecting the ... Read more

January 15, 2020

Dosing Begins in Study of Immune Checkpoint Inhibitor, Alone or in Combo, for Solid Tumors

News

A Phase 1 trial to treat advanced solid tumors has dosed its first patient with a combination of AGEN1181, a next generation CTLA-4 inhibitor, and the PD-1 inhibitor balstilimab — ... Read more

January 13, 2020January 13, 2020

University of Chicago Researcher Wins Immuno-oncology Award from European Society

News

Thomas Gajewski, professor of cancer immunotherapy and pathology and medicine at University of Chicago Medicine, won the 2019 European Society for Medical Oncology (ESMO) Award for Immuno-Oncology in recognition ... Read more

January 9, 2020January 24, 2020

Dosing Begins in Phase 1 Trial of AGEN1223 Antibody for Advanced Solid Tumors

News

A Phase 1 clinical trial for people with advanced solid cancers has dosed its first participant with Agenus‘ investigational antibody, AGEN1223, a therapy designed to improve immune system efficiency ... Read more

January 8, 2020

BioNTech’s CAR T-cell Therapy, Accompanying Vaccine Demonstrate High Anti-tumor Activity in Solid Tumors, Mouse Study Shows

News

Claudin 6, a cell surface protein involved in cell junction formation, may be a promising target for CAR T-cell therapies against solid tumors, according to a proof-of-concept study in ... Read more

January 3, 2020January 3, 2020

Tislelizumab-Chemo Combo Induces Durable Responses in Patients with Stomach, Esophagus Cancers, Trial Data Show

News

Treatment with Beigene‘s experimental therapy tislelizumab and chemotherapy resulted in durable responses and was overall well-tolerated in Chinese people with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma or esophageal squamous cell carcinoma (ESCC), ... Read more

December 18, 2019December 18, 2019

Adding BL-8040 to Keytruda and Chemo Shows Good Disease Control in Pancreatic Cancer, Phase 2 Trial Shows

News

Treatment with investigational BL-8040, in combination with Keytruda (pembrolizumab) and chemotherapy, leads to promising response and disease control rates in people with metastatic pancreatic cancer who progressed after first-line ... Read more

December 17, 2019December 20, 2019

PharmaMar Asks FDA for Accelerated Approval of Lurbinectedin to Treat Relapsed SCLC

News

PharmaMar is asking the U.S. Food and Drug Administration (FDA) to approve lurbinectedin (PM1183) to treat those with small cell lung cancer (SCLC) whose disease progressed following platinum-based chemotherapy. The ... Read more

Pin It on Pinterest